From the Editor: PARP Inhibitors, Biomarker Research, and Gene Editing
Our physician editor-in-chief highlights the February 2015 issue of The Journal of Targeted Therapies in Cancer.
Alex A. Adjei, MD, PhD
Dear Colleagues,
Welcome to the first issue ofThe Journal of Targeted Therapies in Cancerfor 2015.
The Journal highlights advances in targeted therapies in cancer for oncology professionals in the community who wish to translate this research into practice.The Journalalso includes other cancer therapies and research in precision medicine, a topic that has garnered increased media attention since President Barack Obama announced the Precision Medicine Initiative that promises to further move this research forward.
The Journal of Targeted Therapies in Cancerhas been on top of these clinical advances for the past 3 years, bringing readers the latest in original, peer-reviewed research articles. This issue features an article on antibody drug conjugates, and how these agents may yet fill a void in targeted treatment for breast cancer. You will also find details on PARP-1 inhibitors and their emerging role in the treatment of lung cancer. A third research article involves novel targets in relapsed and relapsed/refractory multiple myeloma.
You will also see news on: biomarker research in gastrointestinal stromal tumors, a collaboration in gene editing, recent trial data in the treatment of pancreatic NETS, and updated information on mutations in breast cancer.
This issue’s Clinical Advances section contains information on the potential of anti-androgen therapy in patients with breast cancer. Another breast cancer feature includes a trial studying a nab-paclitaxel-based chemotherapy combination as first-line treatment for triple-negative metastatic breast cancer. This month also features key opinion leaders in 3 disease states discussing plasma-based molecular profiling.
We hope you enjoy this first issue of 2015, and as always, please send us your suggestions on topics you would like to see us highlight so that we continue to improve JTT to serve your needs.
Alex A. Adjei, MD, PhD
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
January 17th 2025In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.
Read More
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?
January 16th 2025Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Read More
Controversy Swirls Around the Use of CDK4/6 Inhibitors as Adjuvant Breast Cancer Therapy
January 15th 2025CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.
Read More
